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Background/aim: Musculoskeletal findings are common in sickle cell patients and may be confused with inflammatory arthritis. In
addition, complications such as frequent infections may create difficulties while choosing drugs such as steroids, methotrexate, or antiTNFs. Our aim is to reveal whether the treatment is different in sickle cell patients with rheumatic diseases such as rheumatoid arthritis.
Materials and methods: Patients followed by Rheumatology and Hematology divisions of Hatay Mustafa Kemal University Hospital
were retrospectively screened. Excluding patients with musculoskeletal findings associated with sickle cell disease (SCD), patients with
chronic or acute inflammatory arthritis were enrolled into study. Demographic data, disease activities, the drugs used, frequency of
infection, and sickle cell-related crisis before and after rheumatic disease diagnosis-treatment of the patients were examined.
Results: Inflammatory rheumatic disease was detected in 14 of 28 sickle cell patients evaluated in the rheumatology department for
musculoskeletal complaints. Twelve of the patients were female and 2 were male. The median duration of rheumatic disease was 27
months (16.5). Eight of these patients had rheumatoid arthritis, 1 had ankylosing spondylitis, reactive arthritis, gout, connective tissue
disease, undifferentiated monoarthritis, and 1 patient had undifferentiated oligoarthritis. For rheumatic disease, 11 (78.6%) of the
patients were using steroids, 8 (57.1%) hydroxychloroquine, 4 (28.6%) methotrexate and sulfasalazine, 2 (14.3%) leflunomide, 1 (7.1%)
anti-TNF (etanercept), and 1 allopurinol and colchicine. The frequency of SCD-related crisis and annual serious infections before and
after rheumatic disease treatment were similar (p = 0.31).
Conclusion: The clinical manifestations of inflammatory arthritis such as rheumatoid arthritis and sickle cell disease may overlap. The
use of drugs such as steroids, methotrexate, or anti-TNF in sickle cell patients with rheumatic disease is the same as in patients without
sickle cell disease. However, treatment should be individualized in patients with complications such as infection.
Key words: Arthritis, sickle cell disease, steroid, methotrexate, anti-TNF

1. Introduction
Sickle cell disease (SCD) is a hematological disease that can
be seen all over the world and it clinically progresses with
attacks such as hemolytic crisis (HC) and vaso-occlusive
crisis (VOC). The distortion of erythrocytes into a sickle
shape in deoxygenated environment and development of
vaso-occlusion and inflammation in the vessel wall are the
main pathogenic mechanisms. SCD is an important cause
of morbidity and mortality by causing chronic end-organ
damage, in addition to its acute complications [1].
Musculoskeletal symptoms are common in sickle cell
disease. Findings that may require orthopedic surgery, such
as septic arthritis, avascular necrosis, and osteomyelitis, are
important findings during SCD. In addition, extremity pain,
arthralgia, myalgia, arthritis, and dactylitis can be seen [2].
On the other hand, inflammatory arthritis such as
rheumatoid arthritis (RA) is common in the community,

and this situation can create various difficulties in diagnosis
and treatment in those especially with accompanying SCD.
As the symptoms of inflammatory arthritis mimick VOC,
diagnosis of inflammatory arthritis may be delayed in
patients with SCD. Again, due to risk of triggering painful
veno-occlusive crises in SCD, there may be difficulties
while using drugs such as steroids recommended in the
treatment of inflammatory arthritis [3]. In addition, the
concomitant use of drugs such as hydroxyurea (HU) used in
the treatment of SCD and disease modifying antirheumatic
drugs (DMARDs) such as methotrexate (MTX) used in the
treatment of RA have the potential to cause problems in
terms of toxic side effects or drug interactions. Interestingly,
SCD is known to be protective against malaria. However,
diseases such as bacterial infections are an important cause
of mortality in SCD, especially in children [4]. As for the
patients who need to use biological drugs such as anti-TNF
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agents for rheumatic disease, treatment may be delayed due
to the risk of infection.
In this study, we presented the clinical features and
treatments of our patients with SCD who were followed up
with a diagnosis of inflammatory rheumatic disease such
as RA. Our main aim is to show whether the treatment
of inflammatory arthritis in SCD is different and the
secondary aim is to discuss the complications related to
SCD that may develop with these treatments.
2. Method and patients
The study was conducted in an area where SCD is
relatively common [5]. Patients aged 18 years and over
who were followed up by the Hematology department
with the diagnosis of SCD between January 2018 and
June 2020 and who were admitted to the Rheumatology
outpatient clinic due to musculoskeletal complaints
were retrospectively screened. Besides demographic
and clinical characteristics of the patients, laboratory
findings and treatments they received were also evaluated.
Patients, who were diagnosed, followed up and treated for
inflammatory arthritis or rheumatic disease, were included
in the study. The diagnosis of RA was made according
to the 2010 ACR-EULAR criteria, and the diagnosis of
ankylosing spondylitis (AS) was made according to the
1984 Modified New-York criteria [6, 7]. Patients with
other inflammatory arthritis were included in the study if
the disease was chronic (more than 6 weeks) or relapsing
frequently and if they were irrelevant of an SCD venoocclusive crisis. Patients who were not diagnosed with a
rheumatic disease and who had SCD-related findings such
as arthralgia and synovitis associated with attacks (VOC)
such as musculoskeletal complaints were not included in
the study. Patients with genetically confirmed SCD by the
hematologist (GI) were included in the study, and patients
with non-SCD hemoglobinopathy were excluded from the
study. High Performance Liquid Chromatography (HPLC),
a type of hemoglobin electrophoresis method was used
to diagnose the patients. Rheumatic diseases, laboratory
parameters, comorbidities, complications related to SCD,
drugs used and doses, average annual number of SCD
crises in the last 10 years, and average annual number of
serious infections were recorded. Serious infection was
defined as an infection that resulted in death, required
hospitalization, or required parenteral antibiotic therapy
for more than 2 weeks.
SPSS v. 22 for Windows program was used for
statistical analysis. The conformity of the data to normal
distribution was checked with the Shapiro–Wilk analysis
test. The distribution of measurable (quantitative) data was
expressed as mean ± standard deviation. Variables with
nonnormal distribution were expressed as median and
minimum-maximum, or interquartile range (IQR) values.
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The difference between the patient and control groups that
did not fit the normal distribution was analyzed with the
Mann–Whitney U test. The distribution of categorical data
was given as % (percentages). p-values below 0.05 were
considered statistically significant in all tests.
Ethics committee approval of the study was obtained
from the ethics committee of Hatay Mustafa Kemal
University Faculty of Medicine.
3. Results
In total, inflammatory rheumatic disease was found in 14
patients out of 28 patients with hemoglobinopathy who
were examined rheumatologically for musculoskeletal
complaints, after excluding patients with non-SCD
hemoglobinopathies (thalassemia intermedia 3 patients)
and those with SCD diagnosis whose musculoskeletal
complaints were found to be associated with SCD. Twelve
of the patients were female and 2 were male (85.7% female).
The median age of the patients was 41 (16.75) years, and
the median age at diagnosis was 38.5 (15.75) years. The
median duration of rheumatic disease was 27 months
(16.5). Eight of these patients (57.1%) had RA, 1 had
AS, 1 had reactive arthritis, 1 had gout, 1 had connective
tissue disease, 1 had undifferentiated monoarthritis,
and 1 patient had undifferentiated oligoarthritis. Of the
patients, 50% had at least one comorbidity. Rheumatoid
factor (RF) was positive in 6 patients (42.9%), anticyclic
citrulline peptide (CCP) was positive in 4 patients (28.6%),
and antinuclear antibody (ANA) was positive in 2 patients
(14.3%) (Table 1).
In the patient with gout (patient no: 12), uric acid (UA)
level was 11.7 (3–7) mg/dL. In the previous laboratory
findings of the patient, it was determined that he had
chronic hyperuricemia and had acute monoarthritis
attacks for 7–10 days in the first metatarsophalangeal
joints, sometimes in the metatarsals and ankles for the
last 3 years, and he was diagnosed with gout 3 years ago.
The attacks he had about 2 years before gout diagnosis
were estimated to be SCD crises, and there was a delay
of approximately 2 years in the diagnosis of gout. The
patient’s last gout attack was 5 months ago and UA level at
the last visit was 5.8 mg/dL. The patient with AS (patient
no: 9) had radiographic bilateral grade 2 sacroiliitis
and the patient’s HLA B27 was negative. Patients with
undifferentiated monoarthritis and undifferentiated
oligoarthritis did not meet the ASAS (Assesment of
SpondyloArthritis international Society) criteria for
peripheral spondyloarttritis (Table 1).
Among the musculoskeletal complications associated
with SCD, osteoporosis was present in 10 patients (71.4%)
and avascular necrosis (AVN) was present in 5 patients
(35.7). AVN had developed before rheumatic diagnosis
and treatment in all patients. Other SCD-related events
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were autosplenectomy in 8 (57.1%) patients, cholelithiasis
and proteinuria in 5 (35.7%), cholecystectomy in 4 (28.6%),
acute chest in 3 (21.4%), pulmonary hypertension (PHT) in
2 (14.3%), and cerebrovascular accident (CVA) in 1 (7.1%)
patient. Demographic data of the patients, laboratory
findings related to rheumatic disease, comorbidities and
complications related to SCD are shown in Table 1.
Considering all the treatments they received for
rheumatic disease, 11 (78.6%) patients were treated with
steroids, 8 (57.1%) patients with hydroxychloroquine
(HCQ), 4 (28.6%) patients with MTX, 4 (28.6%) patients
with sulfasalazine (SLZ), 2 (14.3%) patients with

leflunomide (LEF), and 1 (7.1%) patient with anti-TNF
(etanercept). The patient diagnosed with gout (patient no:
12) was on colchicine and allopurinol treatment, and had a
history of short-term steroid use during a gout attack. The
patient with AS (patient no: 9) was in remission and did
not use DMARDs or biological drugs and was followed
with nonsteroidal antiinflammatory (NSAI) drugs. The
treatments received by the patients for SCD and rheumatic
disease are shown in Table 2. The number of patients using
HU was 11 (78.6%). Along with HU, 3 patients used MTX,
2 patients LEF, 4 patients SLZ, 6 patients HCQ, and 1
patient allopurinol.

Sickle cell disease
complications

Concomitant disease

Laboratory findings

Duration of
rheumatic disease /
months

Age/years at diagnosis
of rheumatic disease

Rheumatic disease

Age/years, Sex

Patient no.

Table 1. Demographic and clinical data of the patients.

1

38, F

Connective tissue 35

32

ANA +3

Absent

Osteoporosis, autosplenectomy

2

34, F

Undifferentiated
monoarthritis

32

29

-

Absent

Osteoporosis, Avascular necrosis,
autosplenectomy

3

42, F

RA

40

20

CCP >200

HT, Depression

Acute chest, osteoporosis, cholelithiasis,
autosplenectomy, PHT, proteinuria

4

50, F

RA

38

136

RF= 59

HT

Acute chest, osteoporosis, AVN,
cholelithiasis, autosplenectomy,
proteinuria

5

47, F

RA

44

28

RF= 78,
CCP= 178

HT

AVN, osteoporosis, proteinuria

6

37, F

Undifferentiated
oligoarthritis

35

24

RF= 52

Absent

Cholelithiasis, autosplenectomy

7

18, M

RA

16

18

RF= 720

Absent

AVN

8

70, F

RA

64

96

RF= 92
CCP>200

HT, atrial
fibrillation

CVA, Osteoporosis, AVN, cholelithiasis,
autosplenectomy, PHT

9

22, F

AS

18

48

X-ray

Absent

-

10

20, F

RA

17

31

ANA+3

Absent

Acute chest, autosplenectomy

11

58, F

RA

56

20

RF= 504
CCP>200

Absent

Osteoporosis

12

47, M

Gout

44

26

UA= 11.7

CRF

Osteoporosis, autosplenectomy,
proteinuria

13

45, F

Reactive arthritis

45

1

-

Absent

Osteoporosis

14

40, F

RA

39

12

-

Absent

Osteoporosis

Abbreviations: RA: rheumatoid arthritis, AS: Ankylosing spondylitis, RF: rheumatoid factor IU (0–15), CCP: anti-cyclic citrulline
peptide mg/dL (0–10), ANA: antinuclear antibody, UA: uric acid mg/dL, HT: hypertension, CRF: chronic renal failure, PHT: pulmonary
hypertension, AVN: avascular necrosis, CVA: cerebrovascular accident
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Of 8 SCD patients who were diagnosed with RA, 7
were female and 1 was male. Six of these patients were
seropositive and 2 were seronegative. All RA patients were
using DMARDs and/or steroids. The prednisolone dose
of the patients using steroids was <7.5 mg/day. DMARDs
used for RA were MTX (7.5–15 mg/week), LEF (10–20
mg/day), SLZ (1–2 g/day) and HCQ (200-400 mg/day).
One RA patient (patient no: 4) had a history of anti-TNF

(etanercept) use. The same patient was using all the RA
drugs intermittently and irregularly, due to a history of
frequent infections. In the other patients with RA, drug
use was regular. The frequency of SCD-related crisis before
and after rheumatic diagnosis and treatment was similar (p
= 0.31). Again, the annual frequency of serious infections
before and after rheumatic diagnosis and treatment was
similar (p = 0.31). (Tables 2 and 3).

Table 2. Drugs used by the patients and complications.

Treatment of
Patient no. rheumatic
disease

Treatment of
hematological
disease

Serious infection/
year before
rheumatic disease
treatment

Serious infection/
Sickle cell crisis/year Sickle cell crisis/
year after
before rheumatic
year after rheumatic
rheumatic disease
disease treatment
disease treatment
treatment

1

HCQ

HU, exchange

1

0

6

5

2

Steroid

HU, Folic acid,
ASA

0

0

3

3

3

Fe chelation,
MTX, HCQ, steroid folic acid,
exchange

0

0

1

2

4

MTX, LEF, HCQ,
etanercept

HU, Fe chelation,
3
ASA, exchange

4

3

2

5

SLZ, HCQ, steroid

HU, Fe chelation,
0
zinc

0

1

1

6

Steroid

HU, Fe chelation 0

0

1

1

7

SLZ, HCQ, steroid

HU, Fe chelation,
0
exchange

0

1

1

8

Steroid, HCQ, MTX, HU, zinc, folic
LEF
acid

2

1

1

1

9

NSAID

0

0

1

0

10

MTX, HCQ, steroid HU, exchange

1

1

1

1

11

SLZ, HCQ, steroid

HU, exchange

1

1

1

1

12

Colchicine,
allopurinol, steroid

HU, exchange,
Folic acid, ASA, 2
Fe chelation

1

3

3

13

Steroid

HU, zinc

0

0

1

0

14

SLZ, steroid

HU, Folic acid,
Zinc, exchange

0

0

1

1

-

Abbreviations: HCQ: hydroxychloroquine, MTX: methotrexate, SLZ: sulfasalazine, LEF: leflunomide HU: hydroxyurea, ASA:
acetylsalicylic acid, Fe: iron; NSAID: Nonsteroidal antiinflammatory drug.
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Table 3. Complications before and after diagnosis and treatment of rheumatic disease.
Before rheumatologic diagnosis

After rheumatologic diagnosis

p

Frequency of serious infections median (IQR)

0 (1)

0 (1)

0.31

Frequency of sickle cell disease crisis, median (IQR)

1 (2)

1 (1)

0.31

Before rheumatologic diagnosis

After rheumatologic diagnosis

p

0 (0–3)

0 (0–4)

0.31

Frequency of sickle cell disease crisis, median (min–max) 1 (1–6)

1 (0–5)

0.31

Frequency of serious infections median (min–max)

4. Discussion
In this study, we found that conventional DMARDs and
steroids can be used regularly in our adult SCD patients
with inflammatory rheumatic disease. All patients with a
diagnosis of RA used conventional (c) DMARDs (MTX,
LEF, SLZ, and HCQ) and steroids. A patient with RA used
anti-TNF (etanercept), a patient with AS used NSAIDs,
a patient with gout used colchicine and allopurinol.
The use of DMARDs did not constitute an obstacle for
hydroxyurea used in the treatment of SCD. We did not find
a significant increment in the annual number of SCD crisis
and infection in our patients before and after rheumatic
disease diagnosis.
During SCD, acute and transient arthritis can often be
seen in association with VOC. This may make it difficult
to determine the prevalence of inflammatory arthritis in
SCD. Different results have been reported regarding the
prevalence of chronic inflammatory arthritis, such as RA,
in SCD. While the prevalence of RA in SCD was lower
in older studies, in a more recent study, it was found that
the prevalence of RA in SCD patients was similar to the
prevalence of RA in the general population (0.5%–1%),
and the prevalence of RA in SCD patients was found
to be 0.94% [8, 9]. This situation may lead to delayed
diagnosis of RA and more severe disease in areas with a
high prevalence of SCD [10]. In the study by McFarlane
et al., more periarticular osteopenia, erosive arthritis, and
more severe disease index were found in patients with RA,
and it was stated that the possible delay in diagnosis was
higher in patients with both SCD and RA [9]. In our study,
osteopenia was also common, but due to the small sample
size, erosive arthritis or disease severity was not compared
with RA patients without SCD. In our study, no significant
delay in diagnosis was found, considering the age at
diagnosis and mean disease duration of the patients. One
reason for this may be that SCD patients are followed in
a center that is highly experienced in hemoglobinopathy.
In addition, there was no significant difference in the
frequency of hospitalization and infection, before and after
the diagnosis and treatment of RA in our SCD patients
(Table 3).

Except for one of 8 patients with RA who participated
in our study (Case 7), all the patients were female (87.5%).
RF was positive in 75% and anti-CCP in 50% of our RA
patients. Two of our patients (Cases 10 and 14) were
seronegative. The seropositivity rate of our patients with
RA was found to be 75%, which is consistent with the
previous studies. Interestingly, seronegative RA patients in
our study were younger than seropositive patients. Case 8
was the oldest patient in our study and was a 70-year-old
female. The mortality rate is increased in SCD patients,
and the life expectancy of patients in developed countries
is in their 40s and 50s. Infections are an important cause of
mortality in both children and adults. In addition, diseaserelated VOC and organ failure contribute to mortality
[11]. Our patient (case 8) had approximately 6 years of RA
disease duration and was positive for RF and anti-CCP.
She used steroids, MTX, HCQ, and LEF for RA treatment
and the patient was in remission. She had comorbid
hypertension and atrial fibrillation, and also had a history
of SCD-associated CVA, osteoporosis, AVN, cholelithiasis,
autosplenectomy, and PHT. The mean annual number of
infections of the patient before and after RA treatment
was similar. While SCD was thought to be a childhood
disease long ago and the number of patients who came
to adulthood was thought to be lower, life expectancy has
increased with the increase in the quality of care and more
effective treatments over the years [12]. In our study, the
2nd and 3rd elderly patients were a 58-year-old female
(case 11) and a 50-year-old female (case 4), and both
patients had seropositive RA diagnosis. Case 11 was in
remission, RA disease activity was stable with SLZ + HCQ,
and low-dose steroid treatment. However, case 4 was a
patient with erosive RA nonresponding to conventional
DMARDs in need of biological (b) DMARDs and had
a history of frequent hospitalizations due to infection
and other complications of the disease. All the other
patients were under 50 years of age. While mortality
is higher in SCD patients due to acute complications in
childhood, there is an increase in mortality due to chronic
complications in adults [13]. Therefore, the risk of chronic
inflammatory diseases such as RA may additionally
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contribute to mortality. Suppression of RA disease activity
may be an effective factor in reducing the risk of morbidity
and mortality in SCD patients.
However, in SCD patients, there is a risk of interaction
between steroids and immunosuppressive agents such as
MTX used in the treatment of diseases such as RA with
the agents used in the treatment of SCD. In addition,
immunosuppression caused by the drugs may increase the
risk of infection.
In our study, 78.6% of our patients used steroids.
The highest dose used in the acute arthritis period was
15 mg prednisolone and the daily maintenance dose was
equivalent to <7.5 mg prednisolone. Three of our patients
used only steroids in the treatment of arthritis. These
were case 2; 34-year-old woman with undifferentiated
monoarthritis, case 6; 37-year-old woman with
undifferentiated oligoarthritis, and case 13; 47-year-old
female diagnosed with reactive arthritis. Other patients
who used steroids were also using antirheumatic drugs,
in combination. In SCD, corticosteroids are not preferred
by the clinicians because of the concern that they may
increase rebound pain, avascular necrosis, and SCDrelated crisis attacks. However, examples of the side effects
of steroids in SCD are mostly reported in the form of case
reports. In addition, many inflammatory cytokines such
as tumor necrosis factor and interleukins are increased in
SCD patients, especially in case of vaso-occlusive crisis,
and occlusion, ischemia, and organ damage develop after
intense inflammation. There are few controlled studies
regarding the reduction of SCD crises by suppressing the
inflammation with steroids in SCD patients [14]. However,
SCD crises after intraarticular steroid injection have been
described in the literature [15]. It has also been reported
that the use of corticosteroids increases the frequency
of hospitalization and may cause vaso-occlusive attacks
[16, 17]. On the contrary, there are studies showing
that steroids can be used in SCD patients and even that
steroids can contribute positively to complications such
as acute chest syndrome [18-21]. In our study, no steroidinduced SCD-related crisis was detected in any of the
patients using steroids. Besides, all of our patients with a
history of avascular necrosis that may be associated with
both SCD and steroids, this complication occurred before
the diagnosis of rheumatic disease and steroid use. In the
literature, it is seen that especially patients who develop
VOC use high-dose corticosteroids [17]. However, none
of our patients used high-dose steroids. The absence of
SCD-related crisis in our patients may be related to the
use of low dose steroids in our patients. NSAI drugs can
be used in SCD patients. However, they should be used
with caution, by considering the potential risk factors
such as gastrointestinal, renal, and cardiac side effects
[22].
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MTX is usually the drug of first choice in the treatment
of RA patients. Apart from this, cDMARDs such as LEF,
SLZ, and HCQ and bDMARDs such as anti-TNF are used
in current RA treatment [23]. In our study, 4 patients
(28.6%) with a diagnosis of RA were using MTX and 3 of
these patients were receiving HU concurrently. The dose of
MTX was 7.5–15 mg/week, and all patients were using folic
acid. There are case reports in the literature regarding the
use of MTX in patients with SCD with rheumatic disease,
and it has been reported that there were patients who used
the drug without any problems, as well as patients with an
increased frequency of VOC when used with steroids [24,
25]. On the other hand, in a study examining the effects of
MTX on VOC in SCD, it was reported that although MTX
did not reduce the frequency and intensity of VOC crisis,
it reduced chronic pain and had positive effects on quality
of life in SCD patients [26]. In our study, we did not find an
increase in the frequency of infection and VOC in patients
using MTX, either with or without a history of steroid use.
There are very limited data related to other cDMARDs
such as LEF, SLZ, and HCQ used in the treatment of RA in
SCD patients [25, 27-30]. Among our patients, 2 patients
used LEF, 4 patients SLZ, and 8 patients used HCQ as
monotherapy or in combination therapy. The doses of these
agents are standard doses used in patients without SCD.
bDMARDs, such as anti-TNFs, are highly effective
agents that can be used in many inflammatory arthropathies,
especially RA. They are generally preferred in rheumatic
patients with severe disease activity who do not respond to
first-line treatments. However, undesirable side effects such
as increased frequency of infection and activation of latent
tuberculosis may be observed. Therefore, special attention
should be paid to infection while using these drugs in SCD
patients. However, there is no data regarding the increased risk
of infection with bDMARDs in patients with SCD compared
to those without SCD. There are case reports regarding the
use of both anti-TNF agents and other biological drugs such
as rituximab in SCD patients, and in general, the side-effect
profile appears to be similar to that of patients without SCD
[31-33]. We had a patient with SCD who used bDMARDs
for RA, and the patient could not tolerate the drug due to
frequent infections (case 4). However, the patient had a
history of frequent hospitalizations due to serious infections
before using anti-TNF agents.
Although our study was conducted at a site where
SCD patients are relatively common, it was conducted in a
single center. One of the limitations of the study is that the
data of the patients were collected retrospectively. Again,
the small number of patients restricts the generalizability
of the data. However, considering the scarcity of studies on
the coexistence of SCD and rheumatic diseases, the results
obtained may be helpful in making the treatment decision
of the patients.
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As a result, clinical findings of SCD and inflammatory
arthritis like RA may overlap, and diagnosis and treatment
of rheumatic diseases may be delayed. The use of steroids,
cDMARDs or bDMARDs in SCD patients with rheumatic
disease is the same as in patients without SCD. These drugs

should be used, by considering the risk of infection, and
the treatment should be decided individually.
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